Brain natriuretic peptide, survival and response to targeting therapy: Another piece in the complex puzzle of Eisenmenger syndrome

Heart

Volumn 98, Issue 9, 2012, Pages 681-682

  D'Alto, Michele ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PHOSPHODIESTERASE III INHIBITOR;

CLINICAL DECISION MAKING; CONGESTIVE HEART FAILURE; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; DRUG TARGETING; EDITORIAL; EISENMENGER COMPLEX; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; KIDNEY FAILURE; MORTALITY; OXYGEN SATURATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; TREATMENT RESPONSE;

CARDIAC SURGICAL PROCEDURES; EISENMENGER COMPLEX; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN;

EID: 84860166027     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301832     Document Type: Editorial

References (20)

1. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
2. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. (Pubitemid 34764819)
3. Dokainish H, Zoghbi WA, Lakkis NM, et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol 2005;45:1223-6. (Pubitemid 40523141)
4. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
5. Diller GP, Alonso-Gonzalez R, Kempny A, et al. Brain natriuretic peptide (BNP) concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart 2012;98:736-42.
6. Porapakkham P, Zimmet H, Billah B, et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010;170:507-14.
7. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010;31:1124-31.
8. D'Alto M, Romeo E, Argiento P, et al. Bosentansildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012;155:378-82.
9. Somerville J. How to manage the Eisenmenger syndrome. Int J Cardiol 1998;63:1-8. (Pubitemid 28060219)
10. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998;19:1845-55. (Pubitemid 28556655)
11. Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol 1999;84:677-81. (Pubitemid 29417960)
12. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006;27:1737-42. (Pubitemid 44025362)
13. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010;121:20-5.
14. Post MC, Janssens S, Van de Werf F, et al. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 2004;25:1651-6. (Pubitemid 39209286)
15. D'Alto M, Romeo E, Argiento P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart 2010;96:1475-9.
16. Law YM, Keller BB, Feingold BM, et al. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 2005;95:474-8. (Pubitemid 40247541)
17. Perlowski AA, Aboulhosn J, Castellon Y, et al. Relation of brain natriuretic peptide to myocardial performance index in adults with congenital heart disease. Am J Cardiol 2007;100:110-14. (Pubitemid 46961907)
18. Giannakoulas G, Dimopoulos K, Bolger AP, et al. Usefulness of natriuretic peptide levels to predict mortality in adults with congenital heart disease. Am J Cardiol 2010;105:869-73.
19. Rabinovitch M, Keane JF, Norwood WI, et al. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 1984;69:655-67.
20. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83. (Pubitemid 19072485)